Gland Pharma Q1 FY27 results (Apr–Jun 2026) and concall

Healthcare · Concall AI · Call held 10 Aug 2026

Company page: Gland Pharma share price, financials & guidance record

Gland Pharma delivered a strong Q1 FY27 with robust revenue and profit growth, driven by strong performance in both CDMO and B2B segments and key geographic markets like the US. The company secured a significant strategic manufacturing agreement and continues to invest in capacity expansion and R&D for future growth, despite minor headwinds from forex losses and supply disruptions in some ROW markets.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q1 FY27: revenue up 23.9%, net profit up 35.3% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	1,063	1,011	1,030	1,039	1,074 +1%	1,178 +17%	1,262 +23%	1,287 +24%
Expenses	699	620	636	680	699	756	754	813
EBITDA	364	391	394	359	375 +3%	422 +8%	508 +29%	474 +32%
Margin	34%	39%	38%	35%	35%	36%	40%	37%
Other income	58	65	44	55	83	36	106	59
Interest	0	18	3	7	4	0	6	1
Depreciation	42	44	43	44	45	45	43	44
Profit before tax	380	394	391	362	409 +8%	412 +5%	565 +45%	488 +35%
Tax rate	26%	25%	26%	26%	26%	25%	26%	25%
Net profit	282	295	290	269	302 +7%	308 +4%	420 +45%	364 +35%
EPS	17.10	17.91	17.60	16.34	18.33	18.69	25.52	22.09

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls